Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jaguar Health Inc JAGX

Healthcare
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing... see more

Recent & Breaking News (NDAQ:JAGX)

Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.

Accesswire October 7, 2021

Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award

Accesswire September 30, 2021

Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021

Accesswire September 27, 2021

Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs

Accesswire September 23, 2021

REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time

Accesswire September 16, 2021

Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency

Accesswire September 15, 2021

Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market

Accesswire September 14, 2021

Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director

Accesswire September 9, 2021

Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split

Accesswire September 3, 2021

Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders

Accesswire September 3, 2021

Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting

Accesswire August 23, 2021

Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe

Accesswire August 19, 2021

Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea

Accesswire August 17, 2021